undamentalytics Newsletter
Sign in

Ameren income statement

In fiscal 2025, Ameren reported revenue of $8.80bn, up 15.4% on the year before, operating income of $2.03bn (a 23.0% margin) and net income of $1.46bn, or $5.35 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue7,1357,6386,1485,7815,8386,0536,0986,0766,1746,2915,9105,7946,3947,9577,5007,6238,7998,749
Operating income1,4169161,0331,1881,1841,2541,2591,3221,4101,3571,2671,3001,3331,5151,5581,5162,0262,176
Interest expense508497387392398341355382391401381419383486566663776827
Income before tax9564766918298299709481,0411,1051,0581,0161,0321,1521,2551,3401,2701,5971,723
Income tax33232525430731137736338257623718215515717618383136155
Net income612139519−9742895866306535238158288719901,0741,1521,1821,4561,563
Diluted EPS$2.78$0.58$2.15−$4.01$1.18$2.40$2.59$2.68$2.14$3.32$3.35$3.50$3.84$4.14$4.38$4.42$5.35$5.67
Diluted shares (average)220m239m242m243m245m244m244m243m244m246m247m249m258m260m263m267m272m276m
EBITDA2,1241,6621,6351,8211,8501,9642,0362,1572,2862,2952,2692,4532,5522,8882,9903,0403,6383,836

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AEE vs CMSAEE vs CNPAEE vs NIAEE vs PNW

More: Multi-Utilities stocks compared, Utilities sector, rankings of US companies

Figures from Ameren's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ameren.